Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

NCT00810017 | Terminated Phase 2 Results DMC

• 1 other identifier: IIT_H446Us
• Study Type: interventional
• Target: 2
• Locations: 1 country
• Sites: 1

Brief Summary

This study is for women and men who have previously treated metastatic (has spread to other parts in the body), Her2- positive breast cancer. The purpose of this study is to find out what effects (good and bad) the FDA-approved drugs etoposide and trastuzumab have on this type of breast cancer and to determine if these drugs are safe to use together. This research is being done to find more effective treatment for this type of condition. In this study, trastuzumab and etoposide will be given by intravenous infusion (IV; through a vein) on the first 3 days of every 3-week cycle. This is repeated for 6 cycles. After 6 cycles, only trastuzumab will be given until worsening of disease. In this study, a small amount of your tissue that was collected when you had surgery will be evaluated in the lab to look at genetic differences among people and how those differences may affect a response to a specific drug or medicine. This testing will look for a gene called Top2A. Previous studies suggest that people who have both the Top2A and Her2 genes respond to certain chemotherapies (anti-cancer drugs) differently from those who only have the Her2 gene.

Conditions

HER-2 Positive Metastatic Breast Cancer

Keywords

Her2 Positive; Breast Cancer; Metastatic

Outcome Measures

Primary Outcomes (2)

• To Determine ORR of Trastuzumab Combined With Etoposide in Patients With HER2 Positive Metastatic Breast Cancer, and to Assess Toxicity of the Combination of Trastuzumab With Intravenous Etoposide.

  To determine the overall response rate

  The best overall response is the best response recorded from the start of first treatment until the date of first progression or date of death from any cause whichever came first, assessed up to 24 months

• To Determine Efficacy of Trastuzumab Combined With Etoposide in Patients With HER2-positive Metastatic Breast Cancer, and to Assess Toxicity of the Combination of Trastuzumab With Intravenous Etoposide.

  Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

  From the start of first treatment until unacceptable toxicity or date of death, whichever came first, over 24 months

Secondary Outcomes (3)

• Determine Duration of Response

  Stable disease is measured from the start of the treatment until the criteria for progression are met, assessed by CT scans at a minimum interval of 8 weeks over 5 years

• Determine Duration of Response

  Time to disease progression is defined as time from registration date to the date of documented disease progression or death on study, whichever occurs first for 5 years

• Determine Duration of Response

  The progression-free survival rate is defined as the percentage of patients who are without disease progression while on the study treatment at the end of study, over 5 years

Study Arms (1)

Single arm study

EXPERIMENTAL

Etoposide 100mg/m2 daily x 3 days Q3W and Trastuzumab 8mg/kg loading dose then 6mg/kg, then single agent until disease progression

Drug: Etoposide; Drug: Trastuzumab

Interventions

Etoposide DRUG

etoposide 100 mg/m2 daily for 3 days every three weeks for 6 cycles

Also known as: Eposin, Etopophos, Vepesid, VP-16

Single arm study

Trastuzumab DRUG

intravenous trastuzumab 8 mg/kg loading dose and then 6 mg/kg every three weeks and then single agent trastuzumab until progression of disease

Also known as: Herceptin

Single arm study

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Females or males with histologic confirmation of breast carcinoma and diagnosis of metastatic breast adenocarcinoma
• Confirmed HER2 amplification by immunohistochemical staining (IHC) 3+ or FISH amplified (either primary or metastatic).
• Have had any number of prior HER2 targeted therapy containing chemotherapies for treatment of breast cancer
• Measurable extent of disease
• Life expectancy of 3 months or greater
• Patients must have adequate heart function, determined with ECHO or MUGA (ECHO preferred).
• Patients must have adequate bone marrow and organ function
• Patient of childbearing potential must be willing to use an effective means of contraception during their participation on trial
• Greater than 3 weeks from prior radiation or chemotherapy; more than 1 week from prior hormonal therapy; and more than 6 weeks from prior treatment with nitrosoureas or mitomycin.
• No serious intercurrent medical illness.
• Controlled metastatic CNS disease ≥ 3 months
• The ability to understand and willingness to sign a written informed consent form, and to comply with the protocol.

You may not qualify if:

• Pregnant or nursing women
• Patients who are poor medical risk because of other non-malignant systemic disease or active, uncontrolled infection.
• Prior craniospinal radiation, or total body irradiation (TBI).
• Patients receiving G-CSF (filgrastim or pegfilgrastim) or thrombopoietin (or other platelet growth factors) within the 3 weeks prior to enrollment (erythropoietin is allowed).
• Prior chemotherapy within the last 3 weeks (last 6 weeks for nitrosureas/mitomycin).
• Prior radiation therapy within the last 3 weeks; prior radiation therapy to indicator lesion (unless objective disease recurrence or progression within the radiation portal has been documented since completion of radiation).
• Concomitant malignancies or previous malignancies within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
• Current symptoms of angina or uncontrolled arrhythmias, uncontrolled hypertension with systolic blood pressure \>=170 or diastolic blood pressure \>=110.
• Psychiatric illness precluding participation in study
• Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest.
• Carcinomatous meningitis or CNS mets not controlled for ≥ 3 months.

Sponsors & Collaborators

• Medstar Health Research Institute: lead
• Genentech, Inc.: collaborator

Study Sites (1)

Washington Cancer Institute

Washington D.C., District of Columbia, 20010, United States

Location

MeSH Terms

Conditions

Breast Neoplasms; Neoplasm Metastasis

Interventions

Etoposide; etoposide phosphate; Trastuzumab

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Podophyllotoxin; Tetrahydronaphthalenes; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds; Glucosides; Glycosides; Carbohydrates; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Results Point of Contact

• Title: Scientific Center Administrator, Oncology Research
• Organization: MedStar Health Research Institute

Research@MedStar.net

(301) 560-7300

Study Officials

• Sandra M Swain, MD

  Medstar Health Research Institute

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 16, 2008
• First Posted: December 17, 2008
• Study Start: February 1, 2009
• Primary Completion: May 1, 2010
• Study Completion: June 1, 2010
• Last Updated: May 19, 2022
• Results First Posted: May 19, 2022

Record last verified: 2022-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)